GOG-0280

Terminated

Return to Protocol Table

A Phase II Evaluation of the Poly (ADP-Ribose) Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888) (IND#77840) (NSC #737664) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Who Carry a Germline BRCA1 or BRCA2 Mutation

Principal Investigator

Robert Coleman

Status

Terminated

Closed to Accrual

November 15, 2012

Closed to Accrual & Treatment

August 28, 2017

Terminated

January 27, 2018


Disease Site

Gynecologic [GY] Ovarian

Phase

II

Developmental Therapeutics

No

Primary Objective

To estimate the proportion of patients who have objective tumor response (complete or partial).  

To determine the frequency and severity of adverse events associated with treatment with veliparib (ABT-888) as assessed by the Active Version of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.  

Patient Population

Patients who have objective tumor response (complete or partial).  

Target Accrual

51

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.